References
1.Libby P, Luscher T. COVID-19 is, in the end, an endothelial disease,Eur Heart J. 2020;41:3038-3044. doi: 10.1093/eurheartj/ehaa623
2. Martin JH, Head R. A pharmacological framework for integrating treating the host, drug repurposing and the damage response framework in COVID-19. Br J Clin Pharmacol.  2021 Mar;87:875-885. doi: 10.1111/bcp.14551
3. Jensen MP, George M, Gilroy D, Sofat R. Beyond dexamethasone, emerging immuno-thrombotic therapies for COVID-19. Br J Clin Pharmacol.  2021 Mar;87:845-857. doi: 10.1111/bcp.14540
4. Fedson DS. Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola. Ann Transl Med. 2016;4:421. doi: 10.21037/atm.2016.11.03
5. Iqbal Z, Ho JH, Adam S, et al. Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK. Atherosclerosis. 2020;313:126-136. doi: 10.1016/j.atherosclerosis.2020.09.008
6. Cubeddu LX, Seamon MJ. Statin withdrawal: clinical implications and molecular mecha- nisms. Pharmacotherapy. 2006;26:1288-1296. doi: 10.1592/phco.26.9.1288
7. Fonarow GC, Wright RS, Spencer FA, et al. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol. 2005;96:611–616. doi: 10.1016/j.amjcard.2005.04.029
8. Torres-Pena JD, Perez-Belmonte LM, Fuentes-Jimenez F, et al. Prior treatment with statins is associated with improved outcomes of patients with COVID-19: Data from the SEMI-COVID-19 Registry. Drugs.  2021 Mar 29;1-11. doi: 10.1007/s40265-021-01498-x
9. Memel ZN, Lee JJ, Foulkes AS, Chung RT, Thaweethai T, Bloom PP. Statins are associated with improved 28-day mortality in patients hospitalized with SARS-CoV-2 infection. medRxiv.  2021 Apr 6;2021.03.27.21254373. doi: 10.1101/2021.03.27.21254373
10. Gupta A, Madhavan MV, Poterucha TJ, et al. Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19. Nat Commun.  2021 Feb 26;12:1325. doi: 10.1038/s41467-021-21553-1
11. McCarthy CP, Murphy S, Jones-O’Connor M, et al. Early clinical and sociodemographic experience with patients hospitalized with COVID-19 at a large American healthcare system.EclinicalMedicine.  2020;26:100504. doi: 10.1016/j.eclinm.2020.100504
12. De Spiegeleer A, Bronselaer A, Teo JT, et al. The effects of ARBs, ACEis, and statins on clinical outcomes of COVID-19 infection among nursing home residents. J Am Med Dir Assoc.  2020 Jul;21:909-914.e2. doi: 10.1016/j.jamda.2020.06.018
13. Koh KK, Sakuma I, Shimada K, Hayashi T, Quon MJ. Combining potent statin therapy with other drugs to optimize simultaneous cardiovascular and metabolic benefits while minimizing adverse events. Korean Circ J. 2017;47:432-439. doi: 10.4070/kcj.2016.0406
14. Byttebier G, Belmans L, Alexander M, et al. Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and ARBs. Hum Vaccin Immunother. 2021;to be published.
15. Varshney AS, Wang DE, Bhatt AS, et al. Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 registered on ClinicalTrials.gov: a cross-sectional analysis. Am Heart  J. 2021;232:105-115. doi: 10.1016/j.ahj.2020.10.065